Amorphical Enrolls First Patient in Phase 2 Trial Testing Novel Nano-Amorphous Mineral Therapy for Stage IV Pancreatic Cancer
核心洞察
Amorphical (搜索) has enrolled the first patient in a Phase 2 clinical trial evaluating its investigational nano-amorphous mineral-based therapy (搜索) for Stage IV pancreatic cancer (搜索) patients.
The study aims to investigate whether the therapy can extend patient survival by measuring progression-free survival, overall survival, response rate, and quality of life improvements.
The novel technology is designed to selectively buffer the tumor microenvironment (搜索) by normalizing tumor acidity, potentially restoring immune activity and enhancing responses to standard treatments.
Amorphical (搜索) has achieved a significant milestone in pancreatic cancer (搜索) research by enrolling the first patient in its Phase 2 clinical trial evaluating a novel nano-amorphous mineral-based therapy (搜索) for Stage IV pancreatic cancer (搜索). The study, approved by the Helsinki Committee of Shaare Zedek Medical Center and the Israel Ministry of Health, represents a promising new approach to treating one of the most aggressive forms of cancer.
Addressing Critical Unmet Medical Need
Pancreatic cancer (搜索) presents one of the most challenging oncological landscapes, with an estimated 496,000 cases diagnosed globally each year. The disease carries a devastating prognosis, with an overall five-year survival rate of less than 13%, which plummets to just 3% for Stage IV patients. These stark statistics underscore the urgent need for innovative therapeutic approaches.
"Given the urgent need for new therapeutic approaches in pancreatic cancer (搜索), we are proud to be leading this important study," said Dr. Ofer Purim, Director of the Gastrointestinal Tumors Service at Shaare Zedek Medical Center and the study's lead investigator. "Our goal is to investigate whether Amorphical (搜索)'s nano-amorphous mineral-based therapy (搜索) can extend patient survival and improve quality of life for those with this aggressive disease."
Novel Mechanism Targeting Tumor Acidity
Amorphical (搜索)'s proprietary technology addresses a fundamental characteristic of advanced pancreatic cancer (搜索): tumor acidity. This pathological acidification serves as a hallmark of the disease and plays a central role in immune evasion, metastasis, and resistance to therapy. The company's nano-amorphous mineral technology is specifically designed to selectively buffer the tumor microenvironment (搜索), potentially restoring immune activity, reducing tumor aggressiveness, and enhancing responses to standard treatments.
The approach represents a departure from traditional cancer therapies by focusing on normalizing the acidic conditions that enable tumor progression and treatment resistance. This mechanism could potentially address multiple aspects of cancer biology simultaneously.
Trial Design and Objectives
The Phase 2 trial will evaluate several key endpoints to assess the therapy's efficacy. Primary measures include progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). Additionally, the study will assess changes in quality of life using a dedicated questionnaire, recognizing the importance of patient-reported outcomes in advanced cancer care.
Data from this critical trial is expected in Q3 of 2026, providing the medical community with insights into whether this novel approach can meaningfully impact outcomes for Stage IV pancreatic cancer (搜索) patients.
Building on Preclinical Foundation
This Phase 2 trial builds on Amorphical (搜索)'s extensive preclinical research and early clinical data from other indications, which have demonstrated the technology's ability to modulate pathological acidity—a key factor in tumor growth. The progression to Phase 2 testing in pancreatic cancer (搜索) represents a significant advancement in the development of this platform technology.
"First patient enrollment in this trial marks an important milestone for Amorphical (搜索) and for patients battling one of the toughest cancers," said Eden Ben, CEO of Amorphical. "Our vision is to harness the unique properties of our nano-amorphous mineral technology to address the acidic tumor microenvironment (搜索), with the ultimate goal of extending life for patients with Stage IV pancreatic cancer (搜索). We are deeply grateful to the clinical teams and patients who are making this progress possible."